$7.90
+0.00 (+0.01%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where AKTX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
8 interventional · 5 with posted results
Held by 1 tracked-famous manager (JANE STREET GROUP, LLC) · FINRA short interest 1.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Nomacopan (rVA576) in Transplant Associated Thrombotic MicroangiopathyNCT04784455results2025-05-15Number of Participants NOT Requiring a Red Blood Bell Transfusion (Transfusion Independence) for 28 Days or More OR Number of Participants With a Urine Protein Creatinine Ratio Value of ≤ 2 mg/mg Maintained for 28 Days or More.Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: The early termination of this study is a business decision following a portfolio reprioritization plan. The decision is not related to any Efficacy, Safety or Clinical concerns regarding Nomacopan/rVA576 | Drug: nomacopan (rVA576) | Thrombotic Microangiopathies | 10 | 2024-05-15actual | 2025-06-05 |
| Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP)NCT05061771Achievement of Complete Disease RemissionRandomized · Quadruple-masked · Treatment | Phase 3 | Withdrawnsponsor's stated reason: Akari has decided to discontinue AK802 study due to strategic resource allocation decisions. | Drug: nomacopan (rVA576) · Other: Placebo | Bullous Pemphigoid | 0 | 2022-08-01actual | 2025-04-09 |
| Treating Paroxysmal Nocturnal Haemoglobinuria Patients With rVA576NCT03588026HB (Haemoglobin) stabilisation rate and the avoidance of packed red blood cells (PRBC) transfusionsRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: rVA576 · Other: Standard of care (SOC) | Paroxysmal Nocturnal Hemoglobinuria (PNH) | 9 | 2020-09-03actual | 2025-04-09 |
| rVA576 (Coversin) Long Term Safety and Efficacy Surveillance StudyNCT03829449results2025-03-12Long Term Safety and Efficacy of rVA576 (Coversin) Therapy Assessed by AEs, SAEs, Standard Lab Tests and ECG Results.Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: The early termination of this study is a business decision, Akari have made the decision to close their global Phase III PNH program. The decision was not related to any efficacy, safety or clinical concerns regarding Coversin/rVA576. | Drug: rVA576 | Paroxysmal Nocturnal Hemoglobinuria | 15 | 2020-08-29actual | 2025-04-10 |
| Topical rVA576 for Treatment of Atopic KeratoconjunctivitisNCT04037891results2025-02-27Incidence of Ocular TEAERandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: The trial has terminated early due to the disruptions caused by the ongoing COVID-19 pandemic. The decision was not related to any efficacy, safety or clinical concerns regarding rVA576. | Drug: rVA576, rVA576 · Other: Placebo | Keratoconjunctivitis, Atopic, Keratoconjunctivitis, Vernal, Conjunctivitis, Allergic | 12 | 2020-04-30actual | 2025-04-10 |
| rVA576 in Adult Mild to Moderate Bullous Pemphigoid SubjectsNCT04035733Safety parameterOpen-label · Treatment | Phase 2 | Completed | Drug: rVA576 | Bullous Pemphigoid (BP) | 9 | 2020-03-12actual | 2025-04-22 |
| Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 PolymorphismsNCT03427060results2025-05-04Measurement of Serum Lactate Dehydrogenase (LDH)Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Coversin | Paroxysmal Nocturnal Hemoglobinuria (PNH) | 1 | 2018-11-15actual | 2025-05-04 |
| Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH)NCT02591862results2023-07-12Measurement of Ratio of LDH to the Upper Limit of Normal (ULN)Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Coversin | Paroxysmal Nocturnal Haemoglobinuria (PNH) | 1 | 2018-03-20actual | 2023-07-12 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19